About Cell Therapy Pharmaceuticals ShareThis Contact Us

Committee Composition

Highlights | Management | Board of Directors | Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below. * Financial Expert

	Audit Committee	Compensation Committee	Governance and Nominating Committee
Scott V. Ogilvie *	Member		Member
William C. Oldaker *	Member	Member
Sandford D. Smith	Member	Member
Catherine Sohn, Pharm.D.		Member	Member
Stanley I. Westreich *		Member	Member

Information for Investors

ShareThis Copy and Paste

ROCKVILLE, Md., Nov. 12, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported financial results for the three months and nine months ended September 30, 2013 and provided a business and clinical update. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) "The Company reached several major milestones in the third quarter. We completed patient dosing in our Phase Ib trial to treat major depressive disorder with NSI-189, our lead small molecule compound. We also ...